Anthony Magliocco, MD, BSc, FRCPC, FCAP, is former chair of anatomical pathology, director of esoteric laboratory services, and served as medical director of the Morsani Advanced Diagnostic Laboratories at the Moffitt Cancer Center. As a molecular and anatomical pathologist, his main research focuses on development of novel clinical predictive assays for cancer patients. Dr. Magliocco has special expertise in women's cancers and conducts scientific research into the molecular basis of metastasis. Most recently he has founded and serves as the president and CEO of Protean BioDiagnostics, a new biotechnology company focused on accelerating the deployment of precision oncology with a focus on community cancer centers and advanced diagnostics including molecular and genetic analysis, liquid biopsy, and incorporating advanced artificial intelligence to improve the quality and efficiency of cancer diagnostic services.